Abstract
Advanced oral squamous carcinoma (OSC) is typically treated with 5- Fluorouracil (5-FU) based regimens. Capecitabine (CAP) is a thymidine phosphorylase (TP) activated oral fluoropyrimidine, rationally designed to generate 5-FU preferentially within tumours. The high activity of CAP in intestinal and breast cancer suggests that CAP may have a role in the therapy of OSC. This tumour selectively is achieved through exploitation of the significantly higher activity of TP in tumour compared with healthy tissue. In the present study, the epithelial and macrophages TP expression were significantly higher in OSC than in non-dysplastic oral leukoplakia (NDOLP) (p=0.004, p=0.005; respectively). Because OSC is sensitive to 5-FU, and TP expression is significantly higher in OSC than in NDOLP, TP-activated CAP could be a promising therapy worthy of clinical investigation.
Keywords: thymidine phosphorylase, capecitabine, 5-fluorouracile, oral squamous carcinoma, leukoplakia, immunohistochemistry
Letters in Drug Design & Discovery
Title: Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Volume: 1 Issue: 1
Author(s): G. Ranieri, R. Patruno, G. Fiore, G. Saponaro, A. Paradiso and L. Grammatica
Affiliation:
Keywords: thymidine phosphorylase, capecitabine, 5-fluorouracile, oral squamous carcinoma, leukoplakia, immunohistochemistry
Abstract: Advanced oral squamous carcinoma (OSC) is typically treated with 5- Fluorouracil (5-FU) based regimens. Capecitabine (CAP) is a thymidine phosphorylase (TP) activated oral fluoropyrimidine, rationally designed to generate 5-FU preferentially within tumours. The high activity of CAP in intestinal and breast cancer suggests that CAP may have a role in the therapy of OSC. This tumour selectively is achieved through exploitation of the significantly higher activity of TP in tumour compared with healthy tissue. In the present study, the epithelial and macrophages TP expression were significantly higher in OSC than in non-dysplastic oral leukoplakia (NDOLP) (p=0.004, p=0.005; respectively). Because OSC is sensitive to 5-FU, and TP expression is significantly higher in OSC than in NDOLP, TP-activated CAP could be a promising therapy worthy of clinical investigation.
Export Options
About this article
Cite this article as:
Ranieri G., Patruno R., Fiore G., Saponaro G., Paradiso A. and Grammatica L., Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine, Letters in Drug Design & Discovery 2004; 1 (1) . https://dx.doi.org/10.2174/1570180043485725
DOI https://dx.doi.org/10.2174/1570180043485725 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomics Studies in Oncology Towards Personalized Medicine in Public Health: Opportunities and Challenges for OMICS Research in Iran
Current Pharmacogenomics and Personalized Medicine STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry GnRH-Agonist Triggering to Avoid Ovarian Hyperstimulation Syndrome: A Review of the Evidence
Current Drug Targets Ethosomes as Vesicles for Effective Transdermal Delivery: From Bench to Clinical Implementation
Current Clinical Pharmacology Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Inhibition of Aromatase (AR) by Benzyl Azole-Based Compounds
Letters in Drug Design & Discovery Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting
Reviews on Recent Clinical Trials Immunonutrition in Surgical Patients
Current Drug Targets The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Novel Artemisinin-Derived Dimers: Synthesis and Evaluation of Anti-cancer Activities
Letters in Drug Design & Discovery ERRATUM
Current Cancer Drug Targets Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics